GlaxoSmithKline Pharmaceuticals · NSE: GLAXO · BSE: 500660
Q3 FY22 results · Oct–Dec 2021
GlaxoSmithKline Pharmaceuticals reported revenue from operations of ₹815.92 crore (down 4.8% from Q3 FY21) and net profit of ₹150.35 crore (down 3.9% from Q3 FY21) for Q3 FY22 (Oct–Dec 2021), on a consolidated basis.
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 815.92 | 857.20 | −4.8% | 1,009.87 | −19.2% |
| Other income | 10.32 | 14.02 | −26.4% | 14.97 | −31.1% |
| Total income | 826.24 | 871.22 | −5.2% | 1,024.84 | −19.4% |
| Profit before tax | 171.76 | 211.41 | −18.8% | 273.54 | −37.2% |
| Net profit for the period | 150.35 | 156.51 | −3.9% | 204.24 | −26.4% |
| EPS, basic (₹) | 8.88 | 9.24 | −4.0% | 12.06 | −26.4% |
| Net margin (%) | 18.4 | 18.3 | 20.2 |
| Item | Q3 FY22 | Q3 FY21 | YoY | Q2 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 807.98 | 858.42 | −5.9% | 991.53 | −18.5% |
| Other income | 10.50 | 13.87 | −24.3% | 15.05 | −30.2% |
| Total income | 818.48 | 872.29 | −6.2% | 1,006.58 | −18.7% |
| Profit before tax | 170.79 | 212.54 | −19.6% | 271.49 | −37.1% |
| Net profit for the period | 149.63 | 157.35 | −4.9% | 202.65 | −26.2% |
| EPS, basic (₹) | 8.83 | 9.29 | −5.0% | 11.96 | −26.2% |
| Net margin (%) | 18.5 | 18.3 | 20.4 |
Consolidated
- Filed with BSE
- 07 Feb 2022, 17:17 IST
- Board meeting
- 07 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 07 Feb 2022, 17:17 IST
- Board meeting
- 07 Feb 2022
- Period
- 01 Oct 2021 to 31 Dec 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE